← Leaderboards
Corey W. Speers
University Of Michigan At Ann Arbor
$1,193,630
Attributed
$1,193,630
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $403.6K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,193,630 · 2
By mechanism
P50$790,019 · 1
R21$403,611 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Erica E Marsh$25,878,787
- Max S. Wicha$49,028,071
- Justin Adam Colacino$6,608,258
- Stephen P. Ethier$7,520,872
- Celina G Kleer$13,464,529
Others in their field
Other Rising Stars on “Malignant Neoplasms”
- David Annett · Information Management Services, Inc.$35,571,865
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Jon White · Midwest Research Institute$17,594,074
- Carolina Porras · Fundacion Inciensa$10,814,023
- Alanna Maguire · Mayo Clinic Rochester$9,942,431
- Hill Georgette · Integrated Laboratory Systems, Llc$8,700,000
Research focus
Malignant NeoplasmsRadiation TherapyHigh RiskMalignant Breast NeoplasmNonmetastaticRadiation ResistanceDna Repair GeneEstrogen Receptor PositiveIn VitroIonizing RadiationMediatingNonhomologous Dna End JoiningPatient Derived Xenograft ModelRadiationDna DamageBreast Cancer Cell LineBreast Cancer ModelCell LineClinical TrialsHomologous RecombinationCancer Radiation TherapyIn VivoAftercareRadiation Tolerance
Grant awards (5)
Project 3: Credentialing CDK 4/6 inhibitors used with radiation as an effective treatment strategy in locally advanced ER+ and TNBC$261,036
P50 · FY2025 · CA · contact PI
Project 3: Credentialing CDK 4/6 inhibitors used with radiation as an effective treatment strategy in locally advanced ER+ and TNBC$250,596
P50 · FY2024 · CA · contact PI
Project 3: Credentialing CDK 4/6 inhibitors used with radiation as an effective treatment strategy in locally advanced ER+ and TNBC$278,387
P50 · FY2023 · CA · contact PI
Elucidating The Role Of Androgen Receptor (AR) In Mediating Radioresistance In AR-Positive Breast Cancer$221,286
R21 · FY2022 · CA · contact PI
Elucidating the role of androgen receptor (AR) in mediating radioresistance in AR-positive breast cancer$182,325
R21 · FY2022 · CA · contact PI